Physician profile
Travis Parker
NPI 1508484288
$1,974.83
in general payments reported to CMS, 2019-2025
10 companies · $430 in 2025
The $430 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $372 · 2023: $648 · 2024: $526 · 2025: $430.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,603.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,603.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $669.39 | 2023-2025 | |
| Alcon Vision LLC | $476.85 | 2022-2025 | Hydrus Microstent, Clareon, Eysuvis |
| Bausch & Lomb Americas INC. | $251.26 | 2022-2025 | Miebo, Xiidra |
| Dompe US, INC. | $187.49 | 2024-2025 | Oxervate |
| Sight Sciences, INC. | $159.76 | 2022-2025 | Omni Surgical System |
| Glaukos Corporation | $145.64 | 2024 | Idose |
| Boston Scientific Corporation | $25.32 | 2025 | Wavewriter Alpha Prime 16 |
| Amgen INC. | $22.36 | 2024 | Tepezza |
| Rxsight INC | $21.75 | 2025 | Rxsight Injector Handpiece, Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Carl Zeiss Meditec USA, INC. | $15.01 | 2023 | Artevo 800 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Travis Parker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.